adbe

Adobe (NDQ:ADBE): The 42-year old company behind PhotoShop and PDFs may have an even richer future ahead, driven by AI

Outside the so-called Magnificant Seven stocks, Adobe (NDQ:ADBE) is one of the most well-known by investors, as well as the…

ASX quarterly rebalance

Here are 6 stocks that got promoted in the ASX quarterly rebalance, and 6 that got demoted

On Monday September 23, the ASX quarterly rebalance will be effective. Stocks will be promoted into new indices, while others…

Blackstone Minerals

Blackstone Minerals (ASX:BSX): Straw hats in winter

Blackstone Minerals (ASX:BSX): Summer is coming Back in early 2022, Blackstone Minerals was riding high. The Perth-based resource junior, at…

Private Credit

Private Credit: What is it and why has this US$1tn market become such a popular investment option?

Private credit is a US$1 trillion (A$1.49tn) market and $200bn in Australia alone. It is clearly worth knowing about and…

How Many Shares Should You Buy

How Many Stocks Should You Have in a Portfolio?

The amount of shares to buy can be an instrumental choice that might define your investment strategy and serve as…

Challenger

Challenger (ASX:CGF): Are investors panicking too much?

Shareholders in Challenger (ASX:CGF) didn’t take the news of Apollo’s sell down well. Apollo, a global fund manager, sold half…

Is the September Effect Real

Is the September Effect Real? Here’s What the Historical Data says and The Challenge Facing Investors

One of the perceived market phenomena is the “September Effect,” observed when the monthly returns during the month of September…

iPhone 16

IPhone 16 Launch Event: Should You Buy Apple Stock Now

The highly awaited event of Apple witnessed the launch of the iPhone 16 series on September 9, 2024. It launches…

Invion

Invion (ASX:IVX): Using Photodynamic Therapy to fight cancer

Unless you’re a professional dermatologist, you may not have ever heard of Photodynamic Therapy, let alone thought of it as…

Bio Gene Technology ASX:BTG)

Bio Gene Technology (ASX:BGT): Commercialising a new class of insecticides

Bio Gene Technology (ASX:BGT) ASX-listed AgTech company developing two compounds – Flavocide™ and Qcide™ – as insecticides. Investors may hear…

Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years

If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…

Cann Group

Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017

Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…

CET1 ratio

CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know

In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…

Star Entertainment Group

Star Entertainment Group (ASX:SGR): Where to now in a post-COVID world? Can it avoid a looming cash crunch?

In a July interview with the AFR, Star Entertainment Group boss Steve McCann admitted that his company’s pre-pandemic glory days…

Prescient Therapeutics

Prescient Therapeutics (ASX:PTX): About to take the plunge into a Phase 2 trial against T-Cell Lymphoma

There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…